Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2613

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1
Chunk 2613
---
 research, development or commercialization of product candidates, might lead to additional
    responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming
    and expensive;

    ●
    collaborators
    may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite
    litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;

    ●
    collaborators
    may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;

    ●
    if
    a collaborator of ours is involved in a business combination, the collaborator might deemphasize or terminate the development or
    commercialization of any product candidate licensed to it by us; and

    ●
    collaborations
    may be terminated by the collaborator, and, if terminated, we could be required to raise additional capital to pursue further development
    or commercialization of the applicable product candidates.

If
the collaborations we enter into do not result in the successful discovery, development and commercialization of product candidates or
if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty
payments under such collaboration. All of the risks relating to product development, regulatory approval and commercialization described
in this Annual Report on Form 10-K also apply to the activities of our therapeutic collaborators.

Additionally,
if one of our existing or future collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators
and our perception in the business and financial communities could be adversely affected. In addition, to the extent that any of our
existing or future collaborators were to terminate a collaboration agreement, we may be forced to independently develop these product
candidates, including funding preclinical or clinical trials, assuming marketing and distribution costs and defending intellectual property
rights, or, in certain instances, abandon product candidates altogether, any of which could result in a change to our business plan and
a material and adverse effect on our business, financial condition, results of operations and prospects.

We
face significant competition in seeking appropriate collaborators for our product candidates, and the negotiation process is time-consuming
and complex. In order for us to successfully establish a collaboration for one or more of our product candidates, potential collaborators
must view these product candidates as economically valuable in markets they determine to be attractive in light of the terms that we
are seeking